Lebrikizumab, an investigational interleukin (IL)-13 inhibitor seeking to join an increasingly crowded market for atopic dermatitis treatments, effectively reduced symptoms of the condition (a.k.a. eczema) when combined with topical corticosteroids, researchers reported. In a randomized trial called ADhere — one of three phase III studies that developers Eli Lilly and Almirall have completed for the […]
FRIDAY, Dec. 16, 2022 (HealthDay News) — Adults with atopic dermatitis (AD) have a significantly increased risk for new-onset migraine, according to a letter to the editor published online Oct. 21 in the Journal of the European Academy of Dermatology & Venereology. Ji Hae Lee, from the Catholic University of Korea in Seoul, and colleagues […]
Is there any association between atopic dermatitis severity and peanut sensitivity? Study sheds light We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok Source link
Primary failures vs secondary failures for therapy, differences in pathophysiology across different ethnic groups, and adult-onset disease are 3 key topics that are either being investigated or warrant further study among patients with atopic dermatitis (AD), said Jason Ezra Hawkes, MD, MS, FAAD, board-certified dermatologist and associate professor of dermatology at the University of California […]